U.S. stops distribution of Lilly's COVID-19 therapy due to impact of variants
March 25 (Reuters) - The U.S. government has stopped distribution of Eli Lilly and Co's COVID-19 antibody therapy, bamlanivimab, due to the impact of...
March 25 (Reuters) - The U.S. government has stopped distribution of Eli Lilly and Co's COVID-19 antibody therapy, bamlanivimab, due to the impact of...